Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.

Alzheimer's Centiloid amyloid longitudinal PET quantification reliable accumulation

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
04 Apr 2024
Historique:
revised: 30 01 2024
received: 09 10 2023
accepted: 31 01 2024
medline: 4 4 2024
pubmed: 4 4 2024
entrez: 4 4 2024
Statut: aheadofprint

Résumé

To support clinical trial designs focused on early interventions, our study determined reliable early amyloid-β (Aβ) accumulation based on Centiloids (CL) in pre-dementia populations. A total of 1032 participants from the Amyloid Imaging to Prevent Alzheimer's Disease-Prognostic and Natural History Study (AMYPAD-PNHS) and Insight46 who underwent [ Reliable accumulation in the PNHS was estimated to occur at >3.0 CL/year. Baseline CL of 16 [12,19] best predicted future Aβ-accumulators. Rates of amyloid accumulation were tracer-independent, lower for APOE ε4 non-carriers, and for subjects with higher levels of education. Our results support a 12-20 CL window for inclusion into early secondary prevention studies. Reliable accumulation definition warrants further investigations.

Identifiants

DOI: 10.1002/alz.13761 PMID: 38574374
pubmed: 38574374
doi: 10.1002/alz.13761
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : EPSRC-funded UCL Centre for Doctoral Training in Intelligent, Integrated Imaging in Healthcare (i4health)
ID : EP/S021930/1
Organisme : Department of Health's NIHR- funded Biomedical Research Centre at University College London
Organisme : NIHR Biomedical Research Centre at UCLH
Organisme : Alzheimer's Disease Data Initiative (ADDI)
Organisme : GE HealthCare
Organisme : Innovative Medicines Initiative 2
ID : 115952

Informations de copyright

© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Références

Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357‐367. doi:10.1016/S1474‐4422(13)70044‐9
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388:9‐21. doi:10.1056/NEJMoa2212948
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021;384:1691‐1704. doi:10.1056/NEJMoa2100708
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: the TRAILBLAZER‐ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512‐527. doi:10.1001/jama.2023.13239
Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3‐45 Study: design of a prevention trial for Alzheimer's disease. Alzheimers Dement. 2023;19(4):1227‐1233. doi:10.1002/alz.12748
Sperling RA, Donohue MC, Raman R, et al. Trial of solanezumab in preclinical Alzheimer's disease. N Engl J Med. 2023;389:1096‐1107. doi:10.1056/NEJMoa2305032
Huang L‐K, Chao S‐P, Hu C‐J. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27:18. doi:10.1186/s12929‐019‐0609‐7
McMillan CT, Chételat G. Amyloid “accumulators”: the next generation of candidates for amyloid‐targeted clinical trials? Neurology. 2018;90:759‐760. doi:10.1212/WNL.0000000000005362
Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state‐of‐the‐art review. Eur J Nucl Med Mol Imaging. 2022; 49:3508‐3528. doi:10.1007/s00259‐022‐05784‐y
Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and cognitive decline in initially amyloid‐negative adults. Neurology. 2018;91:e1809‐e1821. doi:10.1212/WNL.0000000000006469
Landau SM, Horng A, Jagust WJ. Initiative F the ADN. Memory decline accompanies subthreshold amyloid accumulation. Neurology. 2018;90:e1452‐e1460. doi:10.1212/WNL.0000000000005354
Collij LE, Mastenbroek SE, Salvadó G, et al. Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. Alzheimers Dement Diagn Assess Dis Monit. 2021;13:e12216. doi:10.1002/dad2.12216
Langford O, Raman R, Sperling RA, Cummings J, Sun C‐K, Jimenez‐Maggiora G, et al. Predicting amyloid burden to accelerate recruitment of secondary prevention clinical trials. J Prev Alzheimers Dis. 2020;7:213‐218. doi:10.14283/jpad.2020.44
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9:197‐210. doi:10.14283/jpad.2022.30
Shcherbinin S, Evans CD, Lu M, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER‐ALZ randomized clinical trial. JAMA Neurol. 2022;79:1015‐1024. doi:10.1001/jamaneurol.2022.2793
Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement J Alzheimers Assoc. 2015;11:1‐15.e4. doi:10.1016/j.jalz.2014.07.003
Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal β‐amyloid change with 18F‐florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567‐574. doi:10.2967/jnumed.114.148981
Rowe C, Doré V, Thurfjell L, et al. Longitudinal assessment of Aβ accumulation in non‐demented individuals: a 18F‐flutemetamol study. J Nucl Med. 2015;56:193.
Bourgeat P, Doré V, Doecke J, et al. Non‐negative matrix factorisation improves Centiloid robustness in longitudinal studies. Neuroimage. 2021;226:117593. doi:10.1016/j.neuroimage.2020.117593
Bourgeat P, Doré V, Burnham SC, et al. β‐amyloid PET harmonisation across longitudinal studies: application to AIBL, ADNI and OASIS3. Neuroimage. 2022;262:119527. doi:10.1016/j.neuroimage.2022.119527
Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer's disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8:414‐424. doi:10.14283/jpad.2021.56
Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces amyloid‐β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019;11:101. doi:10.1186/s13195‐019‐0559‐z
Luckett ES, Schaeverbeke J, De Meyer S, et al. Longitudinal changes in 18F‐Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: methodological considerations. NeuroImage Clin. 2023;37:103321. doi:10.1016/j.nicl.2023.103321
Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017;13:205‐216. doi:10.1016/j.jalz.2016.08.005
Farrell M. Defining the lowest threshold for amyloid‐PET to predict future cognitive decline and amyloid accumulation | neurology. Neurology. 2021;96(4):e619‐e631. doi:10.1212/WNL.0000000000011214
Smith AM, Obuchowski NA, Foster NL, et al. The RSNA QIBA profile for amyloid PET as an imaging biomarker for cerebral amyloid quantification. J Nucl Med. 2023;64:294‐303. doi:10.2967/jnumed.122.264031
Life Radiopharma Berlin GmbH. Neuraceq : EPAR—Product Information. EMEA/H/C/002553. Eur Med Agency; 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/neuraceq
GE HealthCare. Vizamyl : EPAR—Product Information. EMEA/H/C/002557. Eur Med Agency; 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/vizamyl
Eli Lilly. Amyvid : EPAR—Product Information. EMEA/H/C/002422. Eur Med Agency; 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/amyvid
Amadoru S, Doré V, McLean CA, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. Alzheimers Res Ther. 2020;12:22. doi:10.1186/s13195‐020‐00587‐5
La Joie R, Ayakta N, Seeley WW, et al. Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement. 2019;15:205‐216. doi:10.1016/j.jalz.2018.09.001
Reinartz M, Luckett ES, Schaeverbeke J, et al. Classification of 18F‐Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth. Eur J Nucl Med Mol Imaging. 2022;49:3772‐3786. doi:10.1007/s00259‐022‐05808‐7
Collij LE, Salvadó G, Shekari M, et al. Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur J Nucl Med Mol Imaging. 2021;48:2169‐2182. doi:10.1007/s00259‐020‐05174‐2
Cho SH, Choe YS, Kim HJ, et al. A new Centiloid method for 18F‐florbetaben and 18F‐flutemetamol PET without conversion to PiB. Eur J Nucl Med Mol Imaging. 2020;47:1938‐1948. doi:10.1007/s00259‐019‐04596‐x
Su Y, Hornbeck RC, Speidel B, et al. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies. Alzheimers Dement Diagn Assess Dis Monit. 2019;11:180‐190. doi:10.1016/j.dadm.2018.12.008
Su Y, Flores S, Hornbeck RC, et al. Utilizing the Centiloid scale in cross‐sectional and longitudinal PiB PET studies. NeuroImage Clin. 2018;19:406‐416. doi:10.1016/j.nicl.2018.04.022
Matsuda H, Ito K, Ishii K, et al. Quantitative evaluation of 18F‐flutemetamol PET in patients with cognitive impairment and suspected Alzheimer's disease: a multicenter study. Front Neurol. 2021;11:578753.
Salvadó G, Molinuevo JL, Brugulat‐Serrat A, et al. Centiloid cut‐off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:27. doi:10.1186/s13195‐019‐0478‐z
Tudorascu DL, Minhas DS, Lao PJ, et al. The use of Centiloids for applying [ 11 C]PiB classification cutoffs across region‐of‐interest delineation methods. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:332‐339. doi:10.1016/j.dadm.2018.03.006
Lopes Alves I, Collij LE, Altomare D, et al. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020;16:750‐758. doi:10.1002/alz.12069
Collij LE, Farrar G, Valléz García D, et al. The amyloid imaging for the prevention of Alzheimer's disease consortium: a European collaboration with global impact. Front Neurol. 2023;13:1063598.
Lane CA, Parker TD, Cash DM, et al. Study protocol: insight 46 – a neuroscience sub‐study of the MRC National Survey of Health and Development. BMC Neurol. 2017;17:75. doi:10.1186/s12883‐017‐0846‐x
Shekari M, Verwer EE, Yaqub M, et al. Harmonization of brain PET images in multi‐center PET studies using Hoffman Phantom Scan. 2023;10:68. doi:10.1186/s40658-023-00588-x
Burgos N, Cardoso MJ, Thielemans K, et al. Attenuation correction synthesis for hybrid PET‐MR scanners: application to brain studies. IEEE Trans Med Imaging. 2014;33:2332‐2341. doi:10.1109/TMI.2014.2340135
Grecchi E, Foley C, Gispert JD, Wolz R. P3‐434: Centiloid Pet Suvr analysis using the supratentorial white matter as reference region. Alzheimers Dement. 2018;14:P1278. doi:10.1016/j.jalz.2018.06.1797
Coath W, Modat M, Cardoso MJ, et al. Operationalising the Centiloid Scale for [ 18 F]florbetapir PET Studies on PET/MR. Radiology and Imaging; 2022. doi:10.1101/2022.02.11.22270590
Keshavan A, Wellington H, Chen Z, et al. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: a comparison of Lumipulse and established immunoassays. Alzheimers Dement Diagn Assess Dis Monit. 2021;13(1):e12131. doi:10.1002/dad2.12131
Lu K, Nicholas JM, Collins JD, et al. Cognition at age 70: life course predictors and associations with brain pathologies. Neurology. 2019;93:e2144‐e2156. doi:10.1212/WNL.0000000000008534
Saito T, Rehmsmeier M. The precision‐recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PLoS One. 2015;10:e0118432. doi:10.1371/journal.pone.0118432
Villain N, Chételat G, Grassiot B, et al. Regional dynamics of amyloid‐β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB – PET longitudinal study. Brain. 2012;135:2126‐2139. doi:10.1093/brain/aws125
Zammit MD, Tudorascu DL, Laymon CM, et al. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid‐beta accumulation during Alzheimer's disease progression in Down syndrome. Neuroimage. 2021;228:117728. doi:10.1016/j.neuroimage.2021.117728
Chen K, Roontiva A, Thiyyagura P, et al. Improved power for characterizing longitudinal amyloid‐β PET changes and evaluating amyloid‐modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560‐566. doi:10.2967/jnumed.114.149732
Brendel M, Högenauer M, Delker A, et al. Improved longitudinal [18F]‐AV45 amyloid PET by white matter reference and VOI‐based partial volume effect correction. Neuroimage. 2015;108:450‐459. doi:10.1016/j.neuroimage.2014.11.055
Hanseeuw BJ, Malotaux V, Dricot L, et al. Defining a Centiloid scale threshold predicting long‐term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48:302‐310. doi:10.1007/s00259‐020‐04942‐4
Lopes Alves I, Heeman F, Collij LE, et al. Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimers Res Ther. 2021;13:82. doi:10.1186/s13195‐021‐00819‐2
Burnham SC, Laws SM, Budgeon CA, et al. Impact of APOE‐ε4 carriage on the onset and rates of neocortical Aβ‐amyloid deposition. Neurobiol Aging. 2020;95:46‐55. doi:10.1016/j.neurobiolaging.2020.06.001
Mishra S, Blazey TM, Holtzman DM, et al. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype. Brain. 2018;141:1828‐1839. doi:10.1093/brain/awy103
Betthauser TJ, Koscik RL, Jedynak BM, et al. Multi‐method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain. 2022;145(11):4065‐4079.
Nelson ME, Jester DJ, Petkus AJ, Andel R. Cognitive reserve, alzheimer's neuropathology, and risk of dementia: a systematic review and meta‐analysis. Neuropsychol Rev. 2021;31:233‐250. doi:10.1007/s11065‐021‐09478‐4
Lee DH, Seo SW, Roh JH, et al. Effects of cognitive reserve in Alzheimer's disease and cognitively unimpaired individuals. Front Aging Neurosci. 2022;13:784054. doi:10.3389/fnagi.2021.784054

Auteurs

Ariane Bollack (A)

Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK.
ORCID: 0000-0002-9169-7530

Lyduine E Collij (LE)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Amsterdam Neuroscience, Brain Imaging, VU University Amsterdam, Amsterdam, The Netherlands.
ORCID: 0000-0001-6263-1762

David Vállez García (DV)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
ORCID: 0000-0003-3308-3167

Mahnaz Shekari (M)

Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.
Instituto de investigaciones médicas Hospital del Mar (IMIM), Barcelona, Spain.
ORCID: 0000-0003-1336-6768

Daniele Altomare (D)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
ORCID: 0000-0003-1905-8993

Pierre Payoux (P)

Department of Nuclear Medicine, Imaging Pole, Toulouse University Hospital, Toulouse, France.
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, CHU Purpan, Pavillon Baudot, Place du Docteur Joseph Baylac, Toulouse, France.

Bruno Dubois (B)

Department of Neurology, Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.

Oriol Grau-Rivera (O)

Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.

Mercè Boada (M)

Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
ORCID: 0000-0003-2617-3009

Marta Marquié (M)

Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
ORCID: 0000-0002-0660-0950

Agneta Nordberg (A)

Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.

Zuzana Walker (Z)

Division of Psychiatry, University College London, London, UK.
Essex Partnership University NHS Foundation Trust, The Lodge, Wickford, UK.
ORCID: 0000-0001-7346-8200

Philip Scheltens (P)

Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Alzheimercentrum Amsterdam, Amsterdam, The Netherlands.

Michael Schöll (M)

Wallenberg Centre for Molecular and Translational Medicine, The University of Gothenburg, Gothenburg, Sweden.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.

Robin Wolz (R)

IXICO Plc, London, UK.

Jonathan M Schott (JM)

Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.

Rossella Gismondi (R)

Life Molecular Imaging, GmbH, Berlin, Germany.

Andrew Stephens (A)

Life Molecular Imaging, GmbH, Berlin, Germany.
ORCID: 0000-0001-5052-6586

Christopher Buckley (C)

GE HealthCare, Buckinghamshire, UK.

Giovanni B Frisoni (GB)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Bernard Hanseeuw (B)

Department of Neurology, Institute of Neuroscience, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
WELBIO Department, WEL Research Institute, Wavre, Belgium.
ORCID: 0000-0002-3102-6778

Pieter Jelle Visser (PJ)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.

Rik Vandenberghe (R)

Laboratory for Cognitive Neurology, LBI - KU Leuven Brain Institute, Leuven, Belgium.

Alexander Drzezga (A)

Department of Nuclear Medicine, University Hospital Cologne, Universitätsklinikums Köln, Köln, Germany.
Molecular Organization of the Brain, Institute for Neuroscience and Medicine, INM-2), Forschungszentrum Jülich GmbH, Jülich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Maqsood Yaqub (M)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.

Ronald Boellaard (R)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Juan Domingo Gispert (JD)

Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain.
ORCID: 0000-0002-6155-0642

Pawel Markiewicz (P)

Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK.
Computer Science and Informatics, School of Engineering, London South Bank University, London, UK.
ORCID: 0000-0002-3114-0773

David M Cash (DM)

Queen Square Institute of Neurology, University College London, London, UK.
UK Dementia Research Institute at University College London, London, UK.
ORCID: 0000-0001-7833-616X

Gill Farrar (G)

GE HealthCare, Buckinghamshire, UK.

Frederik Barkhof (F)

Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK.
Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Queen Square Institute of Neurology, University College London, London, UK.
ORCID: 0000-0003-3543-3706

Classifications MeSH